Key Points
- Paul Rubin, an insider at BioAge Labs, sold 68,897 shares on December 4 at an average price of $10.19, generating about $702,060, per an SEC filing.
- BIOA opened at $11.61 with a 50-day moving average of $7.34, a one‑year range of $2.88–$20.37, a market cap of $416.2M and a negative P/E of -7.64, reflecting continued volatility for the clinical‑stage biopharma.
- Analyst and institutional interest is mixed: MarketBeat shows a consensus "Hold" and $15 average price target while Citigroup upgraded to a Buy, and hedge funds like Millennium Management and Two Sigma sharply increased their stakes in the third quarter.
BioAge Labs, Inc. (NASDAQ:BIOA - Get Free Report) insider Paul Rubin sold 68,897 shares of the company's stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $10.19, for a total transaction of $702,060.43. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
BioAge Labs Stock Performance
Shares of BIOA stock opened at $11.61 on Friday. The firm has a 50-day moving average price of $7.34. BioAge Labs, Inc. has a one year low of $2.88 and a one year high of $20.37. The stock has a market capitalization of $416.22 million, a P/E ratio of -7.64 and a beta of 1.74.
BioAge Labs (NASDAQ:BIOA - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.11. The firm had revenue of $2.05 million for the quarter.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on BIOA shares. Weiss Ratings restated a "sell (d-)" rating on shares of BioAge Labs in a research note on Thursday, October 30th. Citigroup boosted their price objective on BioAge Labs from $10.00 to $15.00 and gave the stock a "buy" rating in a research report on Wednesday, October 29th. Finally, Wall Street Zen upgraded BioAge Labs from a "sell" rating to a "hold" rating in a research note on Saturday. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, BioAge Labs presently has a consensus rating of "Hold" and an average price target of $15.00.
Check Out Our Latest Stock Report on BioAge Labs
Hedge Funds Weigh In On BioAge Labs
Several institutional investors and hedge funds have recently bought and sold shares of BIOA. Millennium Management LLC raised its stake in shares of BioAge Labs by 749.8% in the third quarter. Millennium Management LLC now owns 306,552 shares of the company's stock valued at $1,803,000 after buying an additional 270,479 shares during the period. Bank of America Corp DE increased its holdings in BioAge Labs by 46.3% in the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company's stock worth $65,000 after acquiring an additional 3,517 shares during the last quarter. Occudo Quantitative Strategies LP purchased a new stake in BioAge Labs in the 3rd quarter worth about $113,000. Two Sigma Investments LP raised its stake in BioAge Labs by 54.3% in the 3rd quarter. Two Sigma Investments LP now owns 99,669 shares of the company's stock valued at $586,000 after acquiring an additional 35,068 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in BioAge Labs by 1,230.0% during the third quarter. BNP Paribas Financial Markets now owns 25,735 shares of the company's stock valued at $151,000 after purchasing an additional 23,800 shares during the last quarter.
BioAge Labs Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
